Guidelines support the use of bridging therapy for UNOS Stage T2 lesions if the wait time is expected to be six months or ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

Mursla Bio, a Cambridge UK and Boston US leader in Extracellular Vesicle (EV) science, has received FDA approval for its lead ...

Gerry said: “I was shocked to find out that I had liver cancer, but also relieved that it had been found early and it hadn’t ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at ...

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

LIVER cancer is the fourth most common cancer in Malaysia and also the fourth leading cause of cancer-related deaths.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.